The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy

The tumor mutational burden (TMB) is increasingly recognized as an emerging biomarker that predicts improved outcomes or response to immune checkpoint inhibitors in cancer. A multitude of technical and biological factors make it difficult to compare TMB values across platforms, histologies, and trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Golkaram, Mahdi, Zhao, Chen, Kruglyak, Kristina, Zhang, Shile, Bilke, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676656/
https://www.ncbi.nlm.nih.gov/pubmed/33166276
http://dx.doi.org/10.1371/journal.pcbi.1008332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676656/
https://www.ncbi.nlm.nih.gov/pubmed/33166276
http://dx.doi.org/10.1371/journal.pcbi.1008332

Ejemplares similares